BMO Capital Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $111
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains a Market Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $100 to $111.
September 13, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' price target has been raised from $100 to $111 by BMO Capital, maintaining a Market Perform rating.
The increase in price target by BMO Capital indicates a positive outlook for Neurocrine Biosciences. This could potentially lead to an increase in the stock price in the short term as it signals the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100